MedTrace Logo

Study of the Efficacy of Losartan on Aortic Dilatation in Patients With Marfan Syndrome

NCT00763893 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 303

Last updated 2015-11-04

No results posted yet for this study

Summary

The purpose of this study is to evaluate if losartan limits aortic dilatation in patients with Marfan syndrome.

Conditions

  • Marfan Syndrome

Interventions

DRUG

placebo

Cover key details of the intervention. Must be sufficiently detailed to distinguish between arms of a study (e.g., comparison of different dosages of drug) and/or among similar interventions (e.g., comparison of multiple implantable cardiac defibrillators). For example, interventions involving drugs may include dosage form, dosage, frequency and duration.

DRUG

Losartan

50 mg/day if \< weight 50 kg 100 mg/day if weight \> 50 kg

Sponsors & Collaborators

  • Assistance Publique - Hôpitaux de Paris

    lead OTHER

Principal Investigators

  • Guillaume JONDEAU, MD, PhD · Assistance Publique - Hôpitaux de Paris

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
10 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-09-30
Primary Completion
2014-01-31
Completion
2014-12-31

Countries

  • France

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00763893 on ClinicalTrials.gov